DARZALEX FASPRO ® menunjukkan penurunan risiko 51 persen dalam kemajuan ke mieloma multipel aktif untuk pasien dengan smoldering mieloma multipel berisiko tinggi
patients with multiple myeloma and 10% of patients with AL amyloidosis. Grade 3-4 systemic administration-related reactions occurred in 1.9% of patients. In patients with multiple myeloma who received DARZALEX FASPRO ® in combination with lenalidomide/dexamethasone or bortezomib/melphalan/prednisone, the most common systemic administration-related reactions were upper respiratory tract infection and pneumonia. Local Reactions In the pooled … Baca Selengkapnya